Redeye initiates coverage of Coegin Pharma, a hub and spoke biotech company with a diverse array of potential revenue streams. Through its three established portfolio companies, Coegin Pharma develops a robust pipeline of first-in-class pharmaceutical and cosmetic products. With a spread-out operational risk and platform-driven optionality, we see an attractive risk-reward profile with ample potential to create increased shareholder value ahead.